<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02544802</url>
  </required_header>
  <id_info>
    <org_study_id>SB-VGH-201102</org_study_id>
    <nct_id>NCT02544802</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Treatment for Primary Osteoarthritis Knee</brief_title>
  <official_title>Treatment of Primary Osteoarthritis of the Knee Joint With Autologous Mesenchymal Stem Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steminent Biotherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steminent Biotherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and preliminary efficacy of autologous&#xD;
      adipose-derived mesenchymal stem cells (ADMSCs) treatment for patients with primary&#xD;
      osteoarthritis knee. Three intra-articular injections of autologous ADMSCs will be performed&#xD;
      to subjects at a weekly interval.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of intra-articular injection of autologous ADMSCs by incidence of adverse events and alterations in vital signs, blood chemistry profiles, complete blood count, urinalysis, and also the physical examination of the knees.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical assessment of visual analogue scale (VAS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical assessment of Short Form 36 questionnaire (SF-36)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical assessment of Western Ontario and McMaster Universities Arthritis Index (WOMAC)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical assessment of Hospital for Special Surgery (HSS) Knee Score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical imaging assessment of knee X-ray</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical imaging assessment of MRI of the knee</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Osteoarthritis Knee</condition>
  <arm_group>
    <arm_group_label>ADMSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three intra-articular injections of ADMSCs at the dose of 8~10x10^6 cells/injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adipose-Derived Mesenchymal Stem Cells</intervention_name>
    <arm_group_label>ADMSCs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has bilateral Kellgren and Lawrence grade II-III primary osteoarthritis as&#xD;
             determined by X-ray.&#xD;
&#xD;
          2. Subject's pain score is 8-13 points (Lequesne's index).&#xD;
&#xD;
          3. Ages between 50-70 years.&#xD;
&#xD;
          4. Signed informed consent from the subject.&#xD;
&#xD;
          5. Female subjects should be post-menopausal women&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject infected with hepatitis B, hepatitis C, HIV, syphilis or HTLV.&#xD;
&#xD;
          2. Subject not suitable for liposuction surgery.&#xD;
&#xD;
          3. Subject with hypersensitivity/allergy to anesthetic.&#xD;
&#xD;
          4. Subject's creatinine values higher than 1.6mg/dl.&#xD;
&#xD;
          5. Subject with body mass index, BMI over 30.&#xD;
&#xD;
          6. Subject's studied knee treated with intra-articular injection therapy within 6 months&#xD;
             prior to screen.&#xD;
&#xD;
          7. Subject has undergone surgery on either side of knee, including fracture surgery,&#xD;
             arthroscopic surgery, meniscus repair surgery, or cruciate ligament reconstruction&#xD;
             surgery.&#xD;
&#xD;
          8. Subject enrolled in any other cell therapy studies within the past 30 days.&#xD;
&#xD;
          9. Subject who the investigator considers inappropriate for the clinical trial due to any&#xD;
             other reasons than those listed above.&#xD;
&#xD;
         10. Subject has a history of gouty arthritis, septic arthritis, rheumatoid arthritis and&#xD;
             any other autoimmune arthritis of the knee joint.&#xD;
&#xD;
         11. Subject has had major medical problems in vital organs, such as; heart, liver, kidney,&#xD;
             or lung.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>September 4, 2015</study_first_submitted>
  <study_first_submitted_qc>September 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2015</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

